Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)

• Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: Complete study duration & 30 days after completion (up to approximately 7.5 months) ] [ Designated as safety issue: Yes ]
  An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of vaccine, whether or not considered related to the medicinal product.
• Number of Participants Experiencing Unexpected Adverse Drug Reactions (ADRs) [ Time Frame: Complete study duration & 30 days after completion (up to approximately 7.5 months) ] [ Designated as safety issue: Yes ]
  An unexpected ADR was defined as an adverse reaction, whose nature, severity, specificity, or outcome is not consistent with the term or description used in the applicable product information.
• Number of Temozolomide Misuse or Abuse Events [ Time Frame: Complete study duration & 30 days after completion (up to approximately 7.5 months) ] [ Designated as safety issue: Yes ]

  Drug abuse was defined as the use of the study drug for a non-therapeutic effect.

  Misuse was defined as use of the study medication in a way that was not prescribed.

• Number of Temozolomide Drug Interactions [ Time Frame: Complete study duration & 30 days after completion (up to approximately 7.5 months) ] [ Designated as safety issue: Yes ]
  Drug interaction was defined as a chemical or physiological reaction that can occur when two different drugs are taken together.
• Efficacy: Number of Participants Experiencing Complete Response (CR), Partial Response (PR), or Stable Disease(SD) [ Time Frame: Complete study duration (up to approximately 6.5 months) ] [ Designated as safety issue: No ]
  The response ratings were based on the judgment of the investigator.

• Occurrence of adverse events. [ Time Frame: Cohort 1 is observed from start of treatment with temozolomide and concomitant radiotherapy until the end of 6 cycles of subsequent temozolomide monotherapy. Cohort 2 is observed from the start of temozolomide treatment until the end of it. ] [ Designated as safety issue: Yes ]
• Efficacy, defined by best tumor response evaluation based on commonly used guidelines for brain tumors like MacDonald criteria, progression free survival, and overall survival until completion of observation. [ Time Frame: Cohort 1 is observed from start of treatment with temozolomide and concomitant radiotherapy until the end of 6 cycles of subsequent temozolomide monotherapy. Cohort 2 is observed from the start of temozolomide treatment until the end of it. ] [ Designated as safety issue: No ]

The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points that are in question and doubt:

• Incidence of adverse events under actual conditions of use (Serious and Nonserious Adverse Events);
• Adverse Drug Reactions not shown in the directions for use (will be stated as Unexpected Adverse Reaction);
• Adverse Event caused by misuse, abuse, or drug interactions;
• Other information concerned with safety or efficacy.

Participants with newly diagnosed glioblastoma multiforme. Participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

• Glioblastoma
• Glioma
• Astrocytoma

• Drug: Temozolomide
  Administration of temozolomide based on the product labeling.
  Other Names:

  • Temodal
  • Temodar
  • SCH 052365
  • MK-7365
• Radiation: Radiotherapy
  Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
  Other Names:

  • Radiation therapy
  • irradiation

Inclusion Criteria:

• Participants who are prescribed with temozolomide by local labeling:

  • participants with newly diagnosed glioblastoma multiforme;
  • participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Exclusion Criteria:

• N/A